India, March 6 -- What have been the major highlights for this fiscal? What are the revenue projections for FY 24-25?

For FY 24-25, we have guided a revenue range of $160-180 million and are on track to meet our projections. This fiscal has been marked by significant milestones e.g., the successful merger of the three incoming businesses, fundraising with participation from marquee investors, successful listing on the NSE and the BSE and significant addition to our customer base.

The listing of OneSource Pharma on the NSE and BSE this year marks a significant milestone in our journey, one that began with a vision to build a one-stop shop for the CDMO sector. Listing will increase our visibility among partners and stakeholders, opening m...